Original Research Article

Prevalence and antibiotic susceptibility of *Streptococcus pyogenes* isolated from pyoderma in a tertiary care hospital, Hyderabad, South India

L N Rao Sadanand¹, Pendru Raghunath*¹

¹Dept. of Microbiology, Dr. VRK Women’s Medical College, Hyderabad, Telangana, India

**A B S T R A C T**

**Introduction:** Pyoderma is a common acute superficial bacterial skin infection which is highly contagious. In the great majority of cases, pyoderma is caused by *Streptococcus pyogenes*, *Staphylococcus aureus*, or both. The present study was carried out to determine the prevalence and antibiotic susceptibility of *S. pyogenes* isolated from pyoderma in Dr. VRK Women’s Teaching hospital.

**Materials and Methods:** Swabs or pus samples were collected from 250 patients attending Dermatology, outpatient department (OPD) of Dr. VRK Women’s Teaching hospital. Samples were inoculated onto 5% sheep blood agar plates and incubated for 24 h at 37°C in a candle jar. BHS isolates were phenotypically identified by standard microbiological techniques, all the isolates presumptively identified as BHS were tested for Bacitracin susceptibility. Presumptive identification of a strain as a Group A Streptococcus (GAS) was also made by PYRase test. Presumptively identified GAS isolates were serogrouped by Lancefield grouping using a commercially available latex agglutination test. *S. pyogenes* isolates were subjected to antimicrobial susceptibility testing by Kirby-Bauer disc diffusion method.

**Results:** BHS were isolated from 30% of samples. Prevalence of BHS was more among 0-10 years age group (38%). BHS were isolated more frequently from males (38.8%). *S. pyogenes* were isolated from 52 (20.8%) samples. All 52 *S. pyogenes* isolates were found to be susceptible to Penicillin G, amoxicillin, ceftriaxone, azithromycin and vancomycin. Erythromycin and clindamycin showed good activity with sensitivity rates of 92.3% & 96.1%, respectively. Resistance to tetracycline (59.6%) and chloramphenicol (23.1%) was commonly seen in *S. pyogenes*.

**Conclusion:** This study reports the prevalence and antibiotic susceptibility of *S. pyogenes* isolated from pyoderma in Dr. VRK Women’s Teaching hospital. Results of this study suggests the peak incidence of pyoderma in children aged 0 to 10 years and male preponderance. Our study also reports high prevalence of tetracycline and chloramphenicol resistance in *S. pyogenes*.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

---

1. **Introduction**

*Streptococcus pyogenes* is responsible for a wide variety of skin and soft tissue infections (SSTIs) worldwide. This bacterium causes impetigo, erysipelas, cellulitis, necrotizing fasciitis, and myonecrosis. Pyoderma, impetigo, and impetigo contagiosa are interchangeable terms used to describe purulent lesions of the skin. Pyoderma is very common acute bacterial infection of the skin infection and it is highly contagious. It is characterized by pustules and crusted erosions. Pyoderma is transmitted by direct contact and patients with pyoderma can easily spread the infection to their close contacts. Pyoderma is prevalent in children of 2-5 years of age.¹ Previous studies have identified several risk factors for impetigo viz., poor hygiene, low socio-economic status, crowding and underlying scabies.²,³

---

*Corresponding author.
E-mail address: raghunathreddyp@gmail.com (P. Raghunath).
Adults may develop impetigo either by contact with children or by fomites. In children, the incidence of impetigo is greatest during the summer months due to the close contact. Lesions are mainly formed on head & neck (65.4%), followed by hands (19.6%), trunk and legs (7.5% each). In pyoderma, most common symptoms are skin lesions, however, in few patients mild lymphadenopathy is also observed. Up to 5% of the patients might develop a complication of pyodermia i.e. acute Post-streptococcal Glomerulonephritis (PSGN). Only few serotypes 1, 4, 12, 25 and 49, known as nephritogenic strains are known to cause PSGN.

Most cases of pyoderma are caused by S. pyogenes, Staphylococcus aureus, or both. S. pyogenes causes pyodermia in tropics and pharyngitis in temperate regions. Bullous impetigo, the second type of disease presentation, is caused exclusively by S. aureus. Prevalence of S. aureus and S. pyogenes from pyoderma has varied over time. In recent decades, S. aureus especially methicillin-resistant S. aureus (MRSA) has been responsible for pyoderma worldwide especially in temperate regions where disease is less common. In contrast pyoderma is very common in tropical regions, carries the greatest risk of sequelae and S. pyogenes is still remained as dominant pathogen in tropics.

At any point of time, over 140 million people are affected with pyoderma; among them 100 million are children. A research study has demonstrated a male predominance. There is limited information on microbiology of pyodermia from high burden contexts and antibiotic susceptibility pattern.

The objectives of this study were:

1. To determine the prevalence of group A Streptococcal pyoderma in patients visiting Dr. VRK Women’s Teaching Hospital & Research Centre.
2. To explore the associations of this microbiology with age & sex.
3. To study the antimicrobial susceptibility pattern of S. pyogenes isolates from pyoderma.

2. Materials and Methods

This is a cross-sectional study, carried out in the Dr VRK Women’s Teaching hospital & Research Centre, a tertiary care hospital, at Azinagar from January 2015 to March 2016. As many as 250 patients attending Dermatology, outpatient department (OPD) of Dr. VRK Women’s teaching hospital were included in this study. Study participants have not received any antibiotic therapy before sample collection.

2.1. Sample collection and processing

Samples were collected from the base of the skin lesion by means of sterile swabs. In case of pustular lesions, the material was collected with a sterile loop after rupturing the pustule with a sterile needle. The demographic profile was taken from each case. Samples were immediately transported at 4°C in a temperature monitored cooler to the Clinical Microbiology Laboratory, where they were processed within 2 hours. Swabs or pus samples were inoculated onto 5% sheep blood agar plates and incubated for 24 hours at 37°C in a candle jar, which can provide an atmosphere of 5% CO2. Culture plates negative for β-haemolytic colonies were incubated for additional 24 hours to allow the growth of slow growers. Beta-haemolytic streptococci (BHS) isolates were phenotypically identified by standard microbiological techniques: which include β-haemolytic activity on sheep’s blood agar, Gram stain revealing Gram positive cocci, and negative catalase test.

All the isolates presumptively identified as BHS were tested for Bacitracin susceptibility. BHS strains inoculated on sheep blood agar plates. Test was performed using 0.04 units Bacitracin discs (Himedia Laboratories, Mumbai, India) as per standard protocol. Bacitracin disc was placed over the medium with the help of sterile forceps and the plates were incubated at 37°C overnight. Isolates with a zone of inhibition ≥ 15 mm diameter were considered as sensitive. Presumptive identification of a strain as a Group A Streptococcus (GAS) was also made on the basis of production of the enzyme L-pyrrolidonyl-beta-naphthylamide (PYRase test). Presumptively identified GAS isolates were serogrouped by Lancefield grouping by a commercially available Streptex™ Rapid kit (Thermo Fisher Scientific, India).

Antibiotic susceptibility testing was done by Kirby-Bauer disc diffusion method. Briefly, 10^5 CFU/mL of bacterial suspensions were inoculated on sheep blood Mueller-Hinton agar plates and incubated in 5% CO2 for 24 to 48 hours at 37°C. S. pyogenes isolates were subjected to antibiotic susceptibility testing by the following antibiotic discs with respective concentration. Penicillin (10 unit), Ceftriaxone (30 μg), Chloramphenicol (30 μg), Amoxicillin (25 μg), Erythromycin (15 μg), Clindamycin (2 μg), Tetracycline (30 μg) Clarithromycin (15 μg), Azithromycin (15 μg) and Vancomycin (30 μg). Clinical Laboratory and Standard Institute (CLSI) guidelines were followed for interpretation of diameters of zone of inhibition.

3. Results

A total of 250 patients attending Skin outpatient department (OPD) of Dr. VRK Women’s teaching hospital were enrolled from January 2015 to March 2016. Among them, 142 (56.8%) were males and 108 (43.2%) were females. In this study, the subjects were divided into four groups based on their age. Majority of the patients belonged to 0-10 years age group (92) followed by 11-20 years age group (77) (Table 1). BHS were isolated from 75 (30%) of 250 patients (Table 1). Prevalence of BHS was more among 0-10 years age group (38%), followed by 11-20 years age group.
BHS were isolated more frequently from males, 48 (38.8%) of 142 specimens compared to females, 27 (25%) of 108 specimens (Table 2). A total of 52 (69.3%) of 75 BHS isolates were susceptible to Bacitracin and identified as GAS by latex agglutination test. In this study, S. pyogenes were isolated from 52 (20.8%) of 250 samples. As many as 23 (30.6%) of 75 BHS isolates were resistant to Bacitracin and presumptively identified as non-group A BHS (NGABHS). By serogrouping, they were further differentiated into group B Streptococci (GBS), group C Streptococci (GSC) and group G Streptococci (GGS) (Table 3).

Table 1: Age wise distribution of BHS isolates

| Age group (Years) | Total number of cases | No of cases positive for BHS | Positive percentage (%) |
|-------------------|-----------------------|----------------------------|-------------------------|
| 0-10              | 92                    | 35                         | 38                      |
| 11-20             | 77                    | 23                         | 29.9                    |
| 21-30             | 43                    | 10                         | 23.25                   |
| ≥31               | 38                    | 07                         | 18.42                   |
| Total             | 250                   | 75                         | 30                      |

Table 2: Sex wise distribution of BHS isolates

| Sex            | Total number of cases | No of cases positive for BHS | Positive percentage (%) |
|----------------|-----------------------|----------------------------|-------------------------|
| Males          | 142                   | 48                         | 33.8                    |
| Females        | 108                   | 27                         | 25                      |

Table 3: Lancefield grouping of BHS isolates

| Serogroup | Number of BHS isolates positive | Positive percentage (%) |
|-----------|---------------------------------|-------------------------|
| A         | 52                              | 69.2                    |
| B         | 05                              | 6.6                     |
| C         | 07                              | 9.3                     |
| G         | 11                              | 14.68                   |

All 52 S. pyogenes isolates were found to be susceptible to Penicillin G, amoxicillin, ceftriaxone, azithromycin and vancomycin (Table 4). Erythromycin and clindamycin showed good activity with 48 (92.3%), 50 (96.1%) isolates, respectively displaying susceptibility. As many as 40 (76.9%) S. pyogenes isolates were susceptible to chloramphenicol (Table 4). Only 21 (40.4%) S. pyogenes isolates were susceptible to tetracycline (Table 4).

4. Discussion

In this study, BHS were isolated from 30% of patients. This result is in agreement with the previous study by Raghunath and colleagues,19 which has reported the prevalence of 33.8%. However, Mehta et al.20 reported higher prevalence (52.8%) of BHS from pyoderma cases. NGABHS were isolated from 9.2% of the samples. Sharma & Bhatia21 have reported the prevalence of NGABHS as 15.3%. In this study, BHS were isolated more frequently from 0-10 years age group (38%). This is in agreement with the previous studies,1,22 which reported the peak incidence of impetigo in children aged 2 to 5 years. In the present study, BHS were isolated more frequently from males (38.8%) compared to females (25%). Male preponderance has also been observed in many other studies.6,20,23,24 Higher prevalence of pyoderma among males could be due to greater involvement of males in outdoor activities, thus exposing them to trauma and infection.

In our study, S. pyogenes were isolated from 20.8% of samples. Brahmadathan & Koshi25 reported the prevalence rate of pyoderma as defined by the isolation of GAS was 10.1% with monthly variations from 2.1% to 17.1%. Bowen et al.2 conducted a systematic review and reported that in children the median prevalence was 12.3%, and pooled prevalence 16.6%.

In our study, we observed that all strains were susceptible to penicillin G. Similar results had been reported in many countries, namely Morocco,26 France,27 and Germany.28 In addition to penicillin G, amoxicillin and ceftriaxone were fully active against S. pyogenes. This result is in agreement with other research reports from Central, Eastern, and Baltic European countries,29 Turkey,30 Nepal,31 where no resistance has been detected to β-lactams among S. pyogenes isolates. All S. pyogenes isolates tested in this study were susceptible to vancomycin. These results are in line with other studies reported in other countries.32,33 For patients who are allergic to penicillin, erythromycin and other macrolides were considered as good alternatives.34 In our study, no resistance was detected for azithromycin where as 7.7% of resistance to erythromycin. This result is in agreement with a research study from UK and Ireland in 2006, where erythromycin resistance was reported as 10.8%, which increased over time.35 Erythromycin resistance rates vary in different geographic areas.36–38 In
this study, clindamycin showed good activity with low rate of resistance (3.9%). Similar results were reported from Japan (1.4%). Germany (1.1%). In this study, 76.9% of S. pyogenes isolates were susceptible to chloramphenicol. Camara et al. reported that Chloramphenicol was sensitive in 82.1% of isolates with the disk diffusion method. Most of the S. pyogenes (59.6%) isolates were resistant to tetracycline. This result is in line with the previous reports from Dakar, Poland, Iran and South Korea.

5. Conclusion
This study reports the prevalence and antibiotic susceptibility of S. pyogenes isolated from pyoderma in a tertiary care hospital, Hyderabad, South India. Results of this study suggests the peak incidence of pyoderma among children aged 0 to 10 years and male preponderance. Our study also reports high prevalence of tetracycline and chloramphenicol resistance in S. pyogenes.

6. Source of Funding
None.

7. Conflict of Interest
All the authors declare that there is no conflict of interest.

References
1. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53:480–7.
2. Bowen AC, Mahé A, Hay RJ, Andrews RM, Steer AC, Tong SYC, et al. The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyoderma. PLoS One. 2015;10:e0136789.
3. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: A systematic review. Lancet Infect Dis. 2015;15(8):960–70.
4. Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis. 2000;30(5):811–8.
5. Sahl WJ, Mathewson RJ. Common facial skin lesions in children. Quintessence Int. 1993;24(7):475–81.
6. Kiriakis KP, Tadros A, Dimou A, Karamanou M, Banaka F, Alexoudi I. Case detection rates of impetigo by gender and age. Infect Med. 2012;20(2):105–7.
7. Scaramuzzino DA, McNiff JM, Bessen DE. Humanized in vivo model for streptococcal impetigo. Infect Immun. 2000;68:2880–7.
8. Kalia A, Spratt BG, Enright MC, Bessen DE. Influence of recombination and niche separation on the population genetic structure of the pathogen Streptococcus pyogenes. Infect Immun. 2002;70:1971–83.
9. Wannamaker LW. Differences between streptococcal infections of the throat and of the skin. N Engl J Med. 1970;282:23–31.
10. Bessen DE, Carapetis JR, Beall B, Katz R, Hibble M, Currie BJ, et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis. 2000;182:1109–16.
11. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: An update. Int J Dermatol. 2003;42:251–9.
12. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859–64.
13. Amagai M, Nishihifi K, Yamaguchi T, Hanakawa Y, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol. 2002;118:845–50.
14. Korting S, Verhagen AP, Suijelkom-Smit LWA, Morris A, Butler CC, Woudjen JC, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2004;(2):CD003261.
15. Geria AN, Schwartz RA. Impetigo update: new challenges in the era of methicillin resistance. Curr. 2010;85(2):65–70.
16. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):865–94.
17. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis. 2012;25(2):145–53.
18. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–34.
19. Raghunath D, Ramakrishnan KR, Chopra TR. Bacteriology & serology of streptococcal pyoderma. Indian J Med Res. 1985;82:495–7.
20. Oehlschlaeger D, Prakash K, Sharma KB. Streptococcal pyoderma and acute glomerulonephritis in children. Indian J Med Res. 1980;71:692–700.
21. Sharma KB, Bhatia SL. Studies on Beta Haemolytic Streptococci isolated in Delhi. Indian J Med Res. 1966;54(6):517–23.
22. Wasserzog O, Valinsky L, Klement E, Bar-Zeev Y, Davidovitch N, Orr N. A cluster of eczyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis. 2009;48(9):1213–9.
23. Chopra A, Puri R, Mittal RR. Correlation of isolates from pyoderma and carrier sites. Indian J Dermatol Venereol Leprol. 1995;61(5):273–5.
24. Parikh DA, Fernandez RJ, Wagle UD. Clinical and bacteriological aspects of pyoderma. J Postgrad Med. 1987;33(4):189–92.
25. Brahmadhathan KN, Koshi G. Epidemiology of streptococcal pyoderma in an orphanage community of a tropical country. J Trop Med Hyg. 1988;91(6):306–14.
26. Benouda A, Sibile S, Ziane Y, Elouennass M, Dahani K, Hassani A. Place of Streptococcus pyogenes in the throat infection in Morocco and overview of its susceptibility to antibiotics. Pathol Biol (Paris). 2009;57(1):76–80.
27. Mariani-Kurkdjian P, Doit C, Deforche D, Brahimi N, Francois M, Abbeele TVD. Current Streptococcus pyogenes resistance sensitivity responsible for acute tonsillopharyngitis in France. Presse Med. 2004;33(11):703–6.
28. Sauerermann R, Gattringer R, Graninger W, Buxbaum A, Georgopoulos A. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 macrolides. Enferm Infecc Microb. 2003;51(1):53–7.
29. Gracia M, Diaz C, Coronel P, Gimeno M, Garcia-Rodas R, Rodriguez-Cerrato V. Antimicrobial susceptibility of Streptococcus pyogenes in central, Eastern, and Baltic European Countries. Diagn Microbiol Infect Dis. 2005;56(1):52–6.
30. Cifci E, Dogru U, Guriz H, Ayse AD, Ince E. Antibiotic susceptibility of Streptococcus pyogenes strains isolated from throat culture of children with tonsillopharyngitis. J Pediatr Med School. 2003;25(1):15–20.
31. Rijal KR, Dhakal N, Shah RC, Timilsina S, Mahato P, Thapa S. Antibiotic susceptibility of group A Streptococcus isolated from throat swab culture of school children in Pokhara, Nepal. Nepal Med Coll J. 2009;11(4):238–40.
32. Oliveira RE, Barros RR, Mendonça CR, Teixeira LM, Castro AC. Antimicrobial susceptibility and survey of macrolide resistance among Streptococcus pyogenes isolated in Rio de Janeiro. Brazil Microb Drug Resist. 2003;9(1):87–91.
33. Loza E, Morosini MI, Pascual A, Tubau F, Alcalá J, Liñares J, et al. Comparative in-vitro activity of daptomycin against Gram-positive microorganisms: SENTRY surveillance Program. Enferm Infect Microbiol Clin. 2002;26(8):489–94.
34. Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin
Infect Dis. 2002;35(2):113–25.
35. Brown DF, Hope R, Livermore DM, Brick G, Broughton K, George RC, et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008;62(Suppl 2):75–85.
36. Alhazmi A, Hurteau D, Tyrrell GJ. Epidemiology of invasive group B streptococcal disease in Alberta, Canada, from 2003 to 2013. J Clin Microbiol. 2016;54:1774–81.
37. Sayyahfar S, Fahimzad A, Naddaf A, Tavassoli S. Antibiotic susceptibility evaluation of group A Streptococcus isolated from children with pharyngitis: A study from Iran. Infect Chemother. 2015;47:225–30.
38. Thornton CS, Grinwis ME, Sibley CD, Parks MD, Rabin HR, Surette MG. Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients. J Med Microbiol. 2015;64:1375–86.
39. Ikebe T, Hirasawa K, Suzuki R, Isobe J, Tanaka D, Katsukawa C. Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A Streptococcal infections. Antimicrob Agents Chemother. 2005;49(2):788–90.
40. Camara M, Dieng A, Boye CSB. Antibiotic Susceptibility of Streptococcus pyogenes Isolated from Respiratory Tract Infections in Dakar, Senegal. Microbiol Insights. 2013;6:71–5.
41. Mlynarczyk G, Mlynarczyc A, Jeljaszewicz J. Epidemiological aspects of antibiotic resistance in respiratory pathogens. Int J Antimicrob Agents. 2001;18(6):497–502.
42. Jasir A, Tanna A, Noorani A, Mirsalehian A, Efstratiou A, Schalen C. High rate of tetracyclin resistance in Streptococcus pyogenes in Iran: an epidemiological study. J Clin Microbiol. 2000;38(6):2103–7.
43. Cha S, Lee H, Lee K, Hwang K, Bae S, Lee Y. The emergence of erythromycin resistant Streptococcus pyogenes in Seoul. Korea J Infect Chemother. 2001;7(2):81–6.

Author biography
I. N Rao Sadanand, Professor

Cite this article: Sadanand LNR, Raghunath P. Prevalence and antibiotic susceptibility of Streptococcus pyogenes isolated from pyoderma in a tertiary care hospital, Hyderabad, South India. Indian J Microbiol Res 2021;8(4):274-278.